633-P: Intermittently Scanned Continuous Glucose Monitoring (isCGM) for T1DM—Psychosocial Outcomes from the FLASH-UK Study

Background and Aims: IsCGM is increasingly used by people with type 1 diabetes. The impact on psychosocial outcomes and experiences reported by intervention participants relative to controls were assessed in a sub-study of the UK multi-centre RCT (n=156, Females 44%, Baseline HbA1c 71±9 mmol/mol, age 44±15) to determine impact on participants’ lived experiences. Methods: mixed-methods sub-study including validated questionnaires (all) and free-text questions (intervention only) exploring diabetes-related distress, device and treatment satisfaction and user experience. Questionnaires were administered at baseline and again at 24 weeks. HCPs also completed questionnaires post-study. Results: isCGM participants reported significantly lower feelings of powerlessness (p=0.045) and management distress (p<0.001) in the Type 1 diabetes distress score than the control participants. There were no significant differences in depression (PHQ-9) or eating disorders measures, but diabetes treatment satisfaction (p<0.001) and glucose monitoring satisfaction (p<0.001) were greater for isCGM participants. Free-text data shows improved quality of life reported by n=33 isCGM participants including better diabetes control, improved control overnight, reduced anxiety and greater understanding of glucose trends and data. Reported downsides were cited by n=39 isCGM participants and included lack of accuracy, poor connectivity and sensor irritation. All participants would continue to use the device if given the choice. HCPs (n=24) reported improved communication and information sharing with participants, with easy access to the data. Their most commonly cited benefit was improved HbA1c. Conclusion: moderate improvements in psychosocial outcomes on validated measures were reported by intervention participants using isCGM. Challenges with technology persist, although these did not dampen enthusiasm by participants for continued use. Disclosure K.Barnard: Advisory Panel; Abbott Diabetes, Roche Diabetes Care, Sanofi, Consultant; LifeScan Diabetes Institute, Tandem Diabetes Care, Inc., Research Support; Novo Nordisk. M.Burns: None. H.Thabit: Advisory Panel; Dexcom, Inc., Roche Diabetes Care, Research Support; Dexcom, Inc., Speaker's Bureau; Eli Lilly and Company. E.G.Wilmot: Advisory Panel; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk, Sanofi, Roche Diabetes Care, Embecta, Consultant; Springer Healthcare, Research Support; Abbott Diabetes, Diabetes UK, Insulet Corporation, Novo Nordisk, NIH - National Institutes of Health, Speaker's Bureau; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk, Sanofi, Ypsomed AG, Glooko, Inc. L.Leelarathna: Advisory Panel; Abbott Diabetes, Medtronic, Insulet Corporation, Sanofi, Research Support; Abbott Diabetes, Novo Nordisk, Speaker's Bureau; Sanofi, Abbott Diabetes. V.P.Taxiarchi: None. M.Evans: Advisory Panel; Zucara Therapeutics, Pila Pharma, Dexcom, Inc., Other Relationship; Novo Nordisk, AstraZeneca, Abbott Diabetes, Speaker's Bureau; Eli Lilly and Company. S.Neupane: Advisory Panel; Quin, Abbott Diabetes, Roche Diabetes Care, Insulet Corporation, Other Relationship; Abbott Diabetes. G.Rayman: Other Relationship; Diabetes UK, Novo Nordisk, Research Support; Abbott Diabetes, Speaker's Bureau; Abbott Diabetes, Lilly Diabetes, Sanofi. S.Lumley: None. I.C.Cranston: Research Support; Eli Lilly and Company, Speaker's Bureau; Abbott Diabetes, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Insulet Corporation, Novo Nordisk, Sanofi, Viatris Inc. P.Narendran: Advisory Panel; Omnipod, Speaker's Bureau; Abbott Diabetes, Lilly Diabetes. C.J.Sutton: None. Funding Diabetes UK (18/0005836)